Rangeley Capital, LLC Arbutus Biopharma Corp Put Options Transaction History
Rangeley Capital, LLC
- $111 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
170Shares Held
101MCall Options Held
674KPut Options Held
682K-
Morgan Stanley New York, NY22.6MShares$74.3 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.2MShares$43.6 Million22.74% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$38 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.98MShares$29.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.74MShares$28.8 Million4.68% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $493M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...